Thiocolchicoside Sustained Release Formulation with Rate Controlling Polymers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional thiocolchicoside formulations exhibit rapid absorption and high initial plasma concentration followed by rapid decline, leading to transient dose dumping and fluctuations, which are detrimental to therapeutic efficacy and patient compliance, necessitating a sustained release formulation that maintains constant drug levels and reduces side effects.
Innovation Solution
A sustained release pharmaceutical formulation containing thiocolchicoside and at least one rate controlling polymer, such as glyceryl behenate, for oral administration, which releases the drug in a controlled manner over an extended period, preventing dose dumping and maintaining requisite blood levels for once daily or twice daily dosing, and utilizing ammonio methacrylate copolymer for pH-independent release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional immediate release formulations of thiocolchicoside are used, then the drug is rapidly absorbed and achieves high initial plasma concentration, but this leads to rapid decline in plasma levels, transient dose dumping, and fluctuations in drug concentration
Solution Approach 1:
The patent changes the release rate parameter of thiocolchicoside from rapid (immediate release) to controlled/sustained release by incorporating rate-controlling polymers such as hydroxypropyl methylcellulose (HPMC), ethyl cellulose, or carboxymethyl cellulose. This parameter change transforms the plasma concentration profile from fluctuating high-peak levels to stable, sustained levels within the therapeutic window, resolving the contradiction between rapid absorption and concentration stability.
Solution Approach 2:
The patent introduces rate-controlling polymers as intermediary substances that mediate between the rapidly absorbed thiocolchicoside and the bloodstream. These polymers form a controlled release matrix that gradually releases the drug, acting as a buffer to prevent both rapid peak formation and subsequent sharp declines, thereby maintaining stable plasma concentrations.
2Stability of the object's composition
If conventional formulations are administered multiple times daily to maintain therapeutic levels, then plasma concentration fluctuations are addressed, but patient compliance deteriorates due to frequent dosing requirements
Solution Approach 1:
The patent implements continuous controlled release of thiocolchicoside over extended periods (24 hours or more) through the use of sustained-release formulations. This continuous release mechanism eliminates the need for multiple daily dosing while maintaining therapeutic plasma levels, thereby improving patient compliance without compromising therapeutic level maintenance.
Solution Approach 2:
The patent creates a dynamic release system where the formulation adapts to maintain constant plasma concentrations over time. The rate-controlling polymers provide a sustained release profile that dynamically adjusts drug release to match metabolic elimination rates, enabling once-daily or twice-daily dosing while maintaining therapeutic efficacy.
3Speed
If high initial plasma concentration is achieved through rapid absorption, then immediate therapeutic effect is obtained, but side effects increase due to transient dose dumping
Solution Approach 1:
The patent applies partial action by releasing only the necessary amount of thiocolchicoside at each time point to maintain therapeutic levels, rather than releasing the entire dose rapidly. The sustained-release formulation provides gradual drug release at controlled rates, preventing the excessive initial concentration that causes dose dumping and associated side effects, while still achieving therapeutic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves a controlled and sustained release of thiocolchicoside, maintaining therapeutic effects for a longer duration, improving patient compliance and reducing side effects by maintaining constant plasma concentrations, and ensuring repeatable and pH-independent release profiles.
Implementation Method 1
sustained release pharmaceutical formulation containing thiocolchicoside and at least one rate controlling polymer
Implementation Method 2
releases the drug in a controlled manner over an extended period
Implementation Method 3
utilizing ammonio methacrylate copolymer for pH-independent release
Data Source
Figure 1
AI summary
Present invention relates to novel sustained release pharmaceutical formulations containing an effective amount of thiocolchicoside or pharmaceutically acceptable salts thereof for oral administration with myorelaxant activity.